These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 19232460

  • 1. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth.
    Yu Z, Wu J, Wu S, Jia P, Tong Y, Wu X, Wang Y.
    Cancer Lett; 2009 Jun 28; 279(1):101-7. PubMed ID: 19232460
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
    Harada H, Hiraoka M, Kizaka-Kondoh S.
    Cancer Res; 2002 Apr 01; 62(7):2013-8. PubMed ID: 11929818
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K.
    Anticancer Res; 2006 Apr 01; 26(2A):1261-70. PubMed ID: 16619533
    [Abstract] [Full Text] [Related]

  • 4. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia.
    Shahrzad S, Lacombe K, Adamcic U, Minhas K, Coomber BL.
    Cancer Lett; 2010 Nov 01; 297(1):75-83. PubMed ID: 20537792
    [Abstract] [Full Text] [Related]

  • 5. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S, Nagasawa H, Uto Y, Hori H, Ohnishi K, Takahashi A, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Oncol Rep; 2005 Aug 01; 14(2):393-400. PubMed ID: 16012721
    [Abstract] [Full Text] [Related]

  • 6. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells.
    Kudo T, Ueda M, Kuge Y, Mukai T, Tanaka S, Masutani M, Kiyono Y, Kizaka-Kondoh S, Hiraoka M, Saji H.
    J Nucl Med; 2009 Jun 01; 50(6):942-9. PubMed ID: 19443598
    [Abstract] [Full Text] [Related]

  • 7. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M, Sasaki Y, Suzuki H, Mita H, Imai K, Shinomura Y, Tokino T.
    Clin Cancer Res; 2009 Jun 01; 15(11):3725-32. PubMed ID: 19458054
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. TAT-ODD-p53 enhances the radiosensitivity of hypoxic breast cancer cells by inhibiting Parkin-mediated mitophagy.
    Zheng R, Yao Q, Xie G, Du S, Ren C, Wang Y, Yuan Y.
    Oncotarget; 2015 Jul 10; 6(19):17417-29. PubMed ID: 26025927
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rational design of shepherdin, a novel anticancer agent.
    Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, Altieri DC.
    Cancer Cell; 2005 May 10; 7(5):457-68. PubMed ID: 15894266
    [Abstract] [Full Text] [Related]

  • 13. Poor intercellular transport and absence of enhanced antiproliferative activity after non-viral gene transfer of VP22-P53 or P53-VP22 fusions into p53 null cell lines in vitro or in vivo.
    Zavaglia D, Lin EH, Guidetti M, Pluquet O, Hainaut P, Favrot MC, Coll JL.
    J Gene Med; 2005 Jul 10; 7(7):936-44. PubMed ID: 15754307
    [Abstract] [Full Text] [Related]

  • 14. Anti-angiogenesis and anti-tumor activity of recombinant anginex.
    Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW.
    Biochem Biophys Res Commun; 2006 Oct 27; 349(3):1073-8. PubMed ID: 16970922
    [Abstract] [Full Text] [Related]

  • 15. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells.
    Sacco E, Metalli D, Spinelli M, Manzoni R, Samalikova M, Grandori R, Morrione A, Traversa S, Alberghina L, Vanoni M.
    Biotechnol Adv; 2012 Oct 27; 30(1):233-43. PubMed ID: 21620943
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG.
    Adv Cancer Res; 2007 Oct 27; 97():321-38. PubMed ID: 17419952
    [Abstract] [Full Text] [Related]

  • 19. Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model.
    Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, Baay M, Meijnders P, Dewilde S, Vermorken JB, Lardon F.
    Cancer Lett; 2009 Dec 28; 286(2):180-8. PubMed ID: 19540039
    [Abstract] [Full Text] [Related]

  • 20. Effect of RasGAP N2 fragment-derived peptide on tumor growth in mice.
    Michod D, Annibaldi A, Schaefer S, Dapples C, Rochat B, Widmann C.
    J Natl Cancer Inst; 2009 Jun 03; 101(11):828-32. PubMed ID: 19470951
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.